SUBSCRIBE
SUBSCRIBE

Affibody to Start Clinical Development of a New Approach for the Diagnosis of Cancer

September 28, 2007 | 
1 min read

STOCKHOLM, Sweden, September 26, 2007. Swedish MPA gives go ahead for the clinical trial of Affibody’s molecular imaging agent designed to improve the diagnosis of HER2-positive breast cancer.

Europe
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac